Immunity for Health

IfH Symposium: Innovations in Antibody-Based Biologics

11 Jun 2026 | Landmark Building, UZ Brussels, Belgium

ExpertiseUpdated on 28 May 2026

Entry portal through the intestinal barrier

Business Development Manager at Ghent University - provaxs

Merelbeke, Belgium

About

Controlled transfer of biological compounds through the intestinal (mucosal) barrier via targeting of the compound to a defined receptor (APN) on the epithelium.

Via selective transcytosis through the intestinal barrier various functions at the level of the intestinal epithelium and beyond can be modulated: i) antigens can be efficiently presented to the gut associated lymphoid tissue (GALT) leading to a protective mucosal immune response and ii) drugs or drug-containing (nano-)particles can be transferred and delivered across the intestinal barrier.

Field

  • Vaccine Development
  • Immunology
  • Immunotherapy
  • Infectious Diseases

Organisation

Ghent University - provaxs

Academic / Research Institution

Merelbeke, Belgium

Similar opportunities

  • Expertise

    Blood-Brain Barrier in vitro to in vivo models

    An Voets

    business developer BIOMED / academic liaison manager Health Campus Limburg DC at Hasselt University - Biomedical Research Institute

    Diepenbeek, Belgium

  • Expertise

    Controlled expression of sa-mRNA

    • Immunology
    • Immunotherapy
    • Clinical Trials
    • Preclinical trials
    • Vaccine Development

    Sven ARNOUTS

    Business Development Manager at Ghent University - provaxs

    Merelbeke, Belgium

  • Expertise

    Angiogenesis in vitro to in vivo toolbox

    An Voets

    business developer BIOMED / academic liaison manager Health Campus Limburg DC at Hasselt University - Biomedical Research Institute

    Diepenbeek, Belgium